Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
Abdulrahman Katib/LinkedIn
Jan 22, 2026, 11:28

Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing

Abdulrahman Katib, Internal Medicine and Adult Thrombosis Consultant at King Faisal Specialist Hospital and Research Center, shared on LinkedIn:

”Cancer-associated thrombosis (CAT) remains one of the highest-risk VTE settings, where we constantly balance recurrent VTE prevention against bleeding risk.

API-CAT evaluated whether a reduced-dose apixaban strategy could maintain efficacy while improving safety during extended anticoagulation.

The trial showed that a lower dose of apixaban (2.5 mg BID) was non-inferior to the standard dose (5 mg BID) for preventing recurrent VTE in patients with active cancer, and it was associated with less bleeding.”

Read the full article here.

Article: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism

Authors: Isabelle Mahé, Marc Carrier, Didier Mayeur, Jean Chidiac, Eric Vicaut, Nicolas Falvo, Olivier Sanchez et al., for the API-CAT Investigators

Abdulrahman Katib on API-CAT Trial's Evaluation of Apixaban Dosing

Stay updated on all scientific advances with Hemostasis Today.

Abdulrahman Kati API-CAT Apixaban cancer CAT Health Hematology Hemostasis Hemostasis News Hemostasis Today Medicine OncoDaily thrombosis VTE
NewsFeed